Report topline results from Phase 3 INDIGO trial in immunoglobulin G4-related disease
Delivered after the deadline (5 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- 5 Jan 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Report topline results year-end 2025 from the Phase 3 INDIGO trial in patients with IgG4-RD.”
What we found
Evidence strength A What the grades mean
Zenas BioPharma reported positive INDIGO Phase 3 topline results in IgG4-RD on January 5, 2026, five days after the year-end 2025 target.
-
A Zenas BioPharma Reports Third Quarter 2025 Financial Results SEC filing reiterating INDIGO topline results expected 'around year-end 2025'
-
B Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) Company press release announcing INDIGO topline results on Jan 5, 2026
-
C Zenas shares crash after top drug misses expectations in immune disease study News coverage confirming results disclosed Jan. 5, 2026
Checked 17 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Zenas BioPharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ZBIO-000196 · Corrections policy